---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-066724"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:53:40.783492+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma's bivamelagon Phase 2 meets endpoints: -9.3% BMI reduction at 14 weeks

## Summary
- BMI reduction -9.3% (600mg, p=0.0004) and -7.7% (400mg, p=0.0002) vs 2.2% increase on placebo.
- Mean reduction >2.8 points in 'most' hunger score on 10-point scale in 600mg and 400mg cohorts.
- Safety consistent with MC4R agonism; one discontinuation due to serious AE (rectal bleeding).
- Rhythm plans End-of-Phase 2 meeting with FDA and EU scientific advice for registrational path.
- Data from 26 of 27 patients continued into open-label extension as of July 7, 2025.

## SEC filing metadata
- accession: 0001104659-25-066724
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465925066724/0001104659-25-066724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465925066724/tm2520203d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-066724
- JSON: https://secwatch.observer/filing/0001104659-25-066724.json
- Plain text: https://secwatch.observer/filing/0001104659-25-066724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.